Lilly Oritavancin Antibacterial Agent NDA Submission Targeted For 2003
Executive Summary
Lilly expects to file an NDA for the antibacterial glycopeptide oritavancin by 2003, Senior VP-Pharmaceutical Products John Lechleiter, PhD, told the J.P. Morgan H&Q Healthcare Conference in San Francisco Jan. 8.
You may also be interested in...
InterMune Oritavancin Marketing Will Quadruple Firm's Sales Force To 200
InterMune will add 150 sales representatives to its 48-person U.S. force over the next three years for launch of Lilly's glycopeptide antibiotic oritavancin.
InterMune Oritavancin Marketing Will Quadruple Firm's Sales Force To 200
InterMune will add 150 sales representatives to its 48-person U.S. force over the next three years for launch of Lilly's glycopeptide antibiotic oritavancin.
Drug Companies, Insurers Can Agree On Broad Medicare Reforms, Lilly Says
Pharmaceutical manufacturers and health insurance companies can agree on broad Medicare reforms and the long-term objective of incorporating drug coverage into an integrated senior benefit, Lilly Chairman Sidney Taurel told a National Press Club luncheon in Washington, D.C. Jan. 18.